Skip to main content
. 2017 Mar 13;13(5):2957–2964. doi: 10.3892/ol.2017.5847

Table II.

Therapeutic efficacy of sorafenib inn patients with intrahepatic cholangiocarcinoma.

Response Cases, n Rate, %
Complete response   0 0.0
Partial response   4 26.7
Stable disease   7 46.7
Progressive disease   4 26.7
Disease control rate 11 73.3
Total 15 100.0